Lithium and neuroleptics in combination: Is there enhancement of neurotoxicity leading to permanent sequelae?

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 951-962

  Goldman, Stephen A ^a,b  

^a United States Food Drug A   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DEPRESSION; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; LITHIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029828535     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04763.x     Document Type: Article

References (82)

1. Ward ME, Musa MN, Bailey L: Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994; 34:280-285.
2. Cade JFJ: Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 36:349-352.
3. Corcoran AC, Taylor RD, Page IH: Lithium poisoning from the use of salt substitutes. JAMA 1949; 139:685-688.
4. Stern RL: Severe lithium chloride poisoning with complete recovery: report of case. JAMA 1949; 139:710-711.
5. Schou M, Amdisen A, Trap-Jensen J: Lithium poisoning. Am J Psychiatry 1968; 125:520-527.
6. Furlong FW, Hendrie H, Luby ED: A two-year clinical experience with lithium. Can Psychiatr Assoc J 1968; 13:489-497.
7. Baldessarini RJ, Stephens JH: Lithium carbonate for affective disorders. I. Clinical pharmacology and toxicology. Arch Gen Psychiatry 1970; 22:72-77.
8. Agulnik PL, DiMascio A, Moore P: Acute brain syndrome associated with lithium therapy. Am J Psychiatry 1972; 129:621-623.
9. Shopsin B, Johnson G, Gershon S: Neurotoxicity with lithium: differential drug responsiveness. Int Pharmacopsychiatry 1970; 5: 170-182.
10. Rifkin A, Quitkin F, Klein DF: Organic brain syndrome during lithium carbonate treatment. Compr Psychiatry 1973; 14:251-254.
11. von Hartitzsch B, Hoenich NA, Leigh RJ, Wilkinson R, Frost TH, Weddel A, Posen GA: Permanent neurological sequelae despite haemodialysis for lithium intoxication. Br Med J 1972; 4:757-759.
12. Cohen WJ, Cohen NH: Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 1974; 230:1283-1287.
13. American Psychiatric Association Task Force on Lithium Therapy: The current status of lithium therapy: report of the APA Task Force. Am J Psychiatry 1975; 132:997-1001.
14. Brust JS: Combining lithium and neuroleptics (letter). Am J Psychiatry 1976; 133:980.
15. Shopsin B, Small JG, Kellams JJ, Milstein V, Moore JE: Reply to Brust (see ref. 14). Am J Psychiatry 1976; 133:980-981.
16. Spring GK: Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 1979; 40:135-138.
17. Spring G, Frankel M: New data on lithium and haloperidol incompatibility. Am J Psychiatry 1981; 138:818-821.
18. Apte SN, Langston JW: Permanent neurological deficits due to lithium toxicity. Ann Neurol 1983; 13:453-455.
19. Donaldson IM, Cuningham J: Persisting neurologic sequelae of lithium carbonate therapy. Arch NeuroJ 1983; 40:747-751.
20. Schou M: Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984; 70:594-602.
21. Baastrup PC, Hollnagel P, Sørensen R, Schou M: Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 1976; 236:2645-2646.
22. Goldney RD, Spence ND: Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143:882-884.
23. Juhl RP, Tsuang MT, Perry PJ: Concomitant administration of haloperidol and lithium carbonate in acute mania. Dis Nerv Syst 1977; 38:675-676.
24. Miller F, Menninger J: Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7:89-91.
25. Miller F, Menninger J: Correlation of neuroleptic dose and neurotoxicity in patients given lithium and a neuroleptic. Hosp Community Psychiatry 1987; 38:1219-1221.
26. Kessel JB, Verghese C, Simpson GM: Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review. J Psychiatry Neurosci 1992; 17:28-30.
27. D'Mello DA, McNeil JA: Sex differences in bipolar affective disorder: neuroleptic dosage variance. Compr Psychiatry 1990; 31: 80-83.
28. Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW: Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994; 151:133-135.
29. Sernyak MJ, Woods SW: Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993; 29:375-381.
30. Peet M, Pratt JP: Lithium: current status in psychiatric disorders. Drugs 1993; 46:7-17.
31. Fogel BS, Goldberg RJ: Neuroleptic malignant syndrome (letter). N Engl J Med 1985; 313:1292.
32. Schou M: The recognition and management of lithium intoxication. In, Johnson FN (ed.): Handbook of Lithium Therapy. Baltimore: University Park Press, 1980; 394-402.
33. Kane JM: Schizophrenia: somatic treatment. In, Kaplan HI, Sadock BJ (eds.): Comprehensive Textbook of Psychiatry. Fifth edition, Volume 1. Baltimore: Williams & Wilkins, 1989; 777-792.
34. Arana GW, Hyman SE: Handbook of Psychiatric Drug Therapy. Second edition. Boston: Little, Brown and Company, 1991.
35. Schatzberg AF, Cole JO: Manual of Clinical Psychophacmacology. Second edition. Washington, DC: American Psychiatric Press, 1991.
36. Nayak RK, Doose DR, Vasavan Nair NP: The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27:144-150.
37. Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, Thavundayil JX, Achim A, Lizondo E, Nayak R: A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol 1986;6(Suppl 1):30S-37S.
38. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, Florio LP: Affective disorders in five United States communities. Psychol Med 1988; 18:141-153.
39. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151(suppl):1-36.
40. Lewis JA: Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2:93-94.
41. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321:1489-1493.
42. Schou M: Lithium treatment: a refresher course. Br J Psychiatry 1986; 149:541-547.
43. Laska E, Varga E, Wanderung J, Simpson G, Logemann GW, Shah BK: Patterns of psychotropic drug use for schizophrenia. Dis Nerv Syst 1973; 34:294-305.
44. Greenblatt DJ, Shader RI, Koch-Weser J: Psychotropic drug use in the Boston area: a report from the Boston Collaborative Drug Surveillance Program. Arch Gen Psychiatry 1975; 32:518-521.
45. Winstead DK, Blackwell B, Eilers MK, Anderson A: Psychotropic drug use in five city hospitals. Dis Nerv Syst 1976; 37:504-509.
46. Mason AS, Nerviano V, DeBurger RA: Patterns of antipsychotic drug use in four southeastern state hospitals. Dis Nerv Syst 1977; 38:541-545.
47. Michel K, Kolakowska T: A survey of prescribing psychotropic drugs in two psychiatric hospitals. Br J Psychiatry 1981; 138:217-221.
48. National Center for Health Statistics: Utilization of psychotropic drugs in office-based ambulatory care: National Ambulatory Medical Care Survey, 1980 and 1981. Advance Data, from Vital and Health Statistics, No. 90. Department of Health and Human Services Publication No. PHS-83-1250. Hyattsville, MD: United States Public Health Service, June 1983.
49. Schmidt LG, Niemeyer R, Müller-Oerlinghausen B: Drug prescribing pattern of a psychiatric university hospital in Germany. Pharmacopsychiatry 1983; 16:35-42.
50. Edwards S, Kumar V: A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984; 145:502-507.
51. Zorc JJ, Larson DB, Lyons JS, Beardsley RS: Expenditures for psychotropic medications in the United States in 1985. Am J Psychiatry 1991; 148:644-647.
52. Johnson DAW, Wright NF: Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990; 156:827-834.
53. Raschetti R, Spila Alegiani S, Diana G, Da Cas R, Traversa G, Pasquini P: Antipsychotic drug prescription in general practice in Italy. Acta Psychiatr Scand 1993; 87:317-321.
54. Anderson DN: A comparison of in-patient and out-patient prescribing. Br J Psychiatry 1989; 154:644-649.
55. Jacobson GA, Friesen WT, Peterson GM, Rumble RH, Polack AE: Psychoactive drug prescribing in the Tasmanian community. Med J Aust 1992; 157:20-24.
56. Smith DF, Shimizu M, Schou M: Lithium absorption, distribution and clearance and body temperature in rats given lithium and haloperidol. Pharmacology 1977; 15:337-340.
57. Lassen E, Vestergaard P, Thomsen K: Renal function of patients in long-term treatment with lithium citrate alone or in combination with neuroleptics and antidepressant drugs. Arch Gen Psychiatry 1986; 43:481-482.
58. Schaffer CB, Batra K, Garvey MJ, Mungas DM, Schaffer LC: The effect of haloperidol on serum levels of lithium in adult manic patients. Biol Psychiatry 1984; 19:1495-1499.
59. Goodnick PJ, Schorr-Cain CB: Lithium pharmacokinetics. Psychopharmacol Bull 1991; 27:475-491.
60. Nemes ZC, Volavka J, Cooper TB, O'Donnell J, Jaeger J: Lithium and haloperidol (letter). Biol Psychiatry 1986; 21:568-569.
61. Nemes ZC, Volavka J, Lajtha A, Cooper TB, Sershen H: Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs. Psychiatry Res 1987; 20:313-316.
62. Gyulai L, Wicklund SW, Greenstein R, Bauer MS, Ciccione P, Whybrow PC, et al: Measurement of tissue lithium concentration by lithium magnetic resonance spectroscopy in patients with bipolar disorder. Biol Psychiatry 1991; 29:1161-1170.
63. 1H-magnetic resonance spectroscopy in bipolar disorder. Psychiatry Res 1992; 45:53-63.
64. Kato T, Shioiri T, Inubushi T, Takahasi S: Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: relationship to erythrocyte and serum concentrations. Biol Psychiatry 1993; 33:147-152.
65. Frazer A, Mendels J, Secunda SK, Cochrane CM, Bianchi CP: The prediction of brain lithium concentrations from plasma or erythrocyte measures. J Psychiatr Res 1973;10:1-7.
66. Renshaw PF, Wicklund S: In vivo measurement of lithium in humans by nuclear magnetic resonance spectroscopy. Biol Psychiatry 1988; 23:465-475.
67. 3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochem Int 1993; 22:395-403.
68. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM: Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 1992; 108:338-344.
69. 18F]haloperidol. Synapse 1992; 11:10-19.
70. Beck PJ, Reis DJ: A toxic interaction between lithium and some psychtropic agents in rat. Res Commun Psychol Psychiatry Behav 1976; 1:269-282.
71. Sawas AH, Gilbert JC: Lipid peroxidation as a possible mechanism for the neurotoxic and nephrotoxic effects of a combination of lithium carbonate and haloperidol. Arch Int Pharmacodyn Ther 1985; 276:301-312.
72. Jenner P, Marsden CD: The substituted benzamides: a novel class of dopamine antagonists. Life Sci 1979; 25:479-485.
73. Keck PE Jr, Seeler DC, Pope HG Jr, McElroy SL: Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome? Biol Psychiatry 1990; 28:58-62.
74. Sethi N, Prakash R, Sethi BB: Effects of administration of haloperidol with lithium in rabbits. Indian J Med Res 1981; 74:754-756.
75. Weisenburg TH: Nervous symptoms following sunstroke. JAMA 1912; 58:2015-2017.
76. Mehta AC, Baker RN: Persistent neurological deficits in heat stroke. Neurology 1970; 20:336-340.
77. Yaqub BA, Daif AK, Panayiotopoulos CP: Pancerebellar syndrome in heat stroke: clinical course and CT scan findings. Neuroradiology 1987; 29:294-296.
78. Naramoto A, Koizumi N, Itoh N, Shigematsu H: An autopsy case of cerebellar degeneration following lithium intoxication with neuroleptic malignant syndrome. Acta Pathol Jpn 1993; 43: 55-58.
79. Lefkowitz D, Ford CS, Rich C, Biller J, McHenry LC Jr: Cerebellar syndrome following neuroleptic induced heat stroke. J Neurol Neurosurg Psychiatry 1983; 46:183-185.
80. Lee S, Merriam A, Kim T-S, Liebling M, Dickson DW, Moore GRW: Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. J Neurol Neurosurg Psychiatry 1989; 52:387-391.
81. Kish SJ, Kleinert R, Minauf M, Gilbert J, Walter GF, Slimovitch C, et al: Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Am J Psychiatry 1990; 147:1358-1363.
82. Pelletier J, Habib M, Pellissier JF, Crevat A, Khalil R: Séquelles neurologiques de l'association neuroleptiques-lithium: rôle de l'hyperthermie. Rev Med Interne 1991; 12:187-191.